Alliqua Biomedical Inc (ALQA) Expected to Announce Earnings of -$0.02 Per Share

Equities analysts forecast that Alliqua Biomedical Inc (NASDAQ:ALQA) will announce earnings of ($0.02) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Alliqua Biomedical’s earnings. Alliqua Biomedical posted earnings of ($0.79) per share during the same quarter last year, which indicates a positive year over year growth rate of 97.5%. The business is expected to announce its next quarterly earnings report on Thursday, November 8th.

According to Zacks, analysts expect that Alliqua Biomedical will report full year earnings of $5.14 per share for the current financial year. For the next year, analysts anticipate that the company will post earnings of ($0.09) per share. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Alliqua Biomedical.

Alliqua Biomedical (NASDAQ:ALQA) last issued its earnings results on Friday, August 10th. The company reported ($0.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.64). The firm had revenue of $0.86 million for the quarter. Alliqua Biomedical had a negative net margin of 99.08% and a negative return on equity of 169.35%.

Shares of ALQA traded up $0.01 during trading hours on Friday, hitting $2.16. The company had a trading volume of 332 shares, compared to its average volume of 9,425. The firm has a market cap of $10.86 million, a price-to-earnings ratio of -0.33 and a beta of 1.12. Alliqua Biomedical has a one year low of $1.58 and a one year high of $3.85.

About Alliqua Biomedical

Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.

Featured Article: Dividend Aristocrat Index

Get a free copy of the Zacks research report on Alliqua Biomedical (ALQA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with's FREE daily email newsletter.

Leave a Reply